Trial Profile
An Open-label Phase Ib, Study, to Determine Safety of Oral AL3810 in Patients With Locally Advanced or Metastatic Gastric, Hepatocellular or Nasopharyngeal Carcinoma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 22 Jun 2022
Price :
$35
*
At a glance
- Drugs Lucitanib (Primary)
- Indications Adenocarcinoma; Biliary cancer; Carcinoma; Gastric cancer; Liver cancer; Malignant thymoma; Nasopharyngeal cancer
- Focus Adverse reactions
- Sponsors Haihe Biopharma; ShangHai HaiHe Pharmaceutical
- 08 Jun 2022 Results assessing safety, tolerability, and preliminary efficacy of lucitanib in recurrent and metastatic nasopharyngeal carcinoma (RM-NPC) published in the Oncologist
- 31 May 2020 Status changed to completed, according to results presented at the 56th Annual Meeting of the American Society of Clinical Oncology
- 31 May 2020 Results presented at the 56th Annual Meeting of the American Society of Clinical Oncology